CERS:NSD-Cerus Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 6.19

Change

+1.06 (+20.66)%

Market Cap

USD 0.88B

Volume

0.01B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.

Company Website : http://www.cerus.com

Address : 1220 Concord Avenue, Concord, CA, United States, 94520

Employees : 262

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.25

52 Week High : 8.87

Short Ratio : 7.35

52 Week Low : 4.67

Shorted Shares : 12,934,934

200 Day Moving Average : 6.06

Shorted Shares Previous Month : 13,131,600

50 Day Moving Average : 5.34

Shares Held By Insiders : 2.59%

Short Percentage : 8.00%

Shares Held by Institutions : 83.17%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+32.54 (+8.42%)

 USD155.19B 259.06 194.72
BNTX BioNTech SE

+62.63 (+17.80%)

 USD79.30B 59.35 50.07
REGN Regeneron Pharmaceuticals, Inc

-5.56 (-0.95%)

 USD62.49B 16.70 12.83
VRTX Vertex Pharmaceuticals Incorpo..

-0.46 (-0.23%)

 USD51.84B 26.37 17.81
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD40.34B 59.23 42.56
BGNE BeiGene, Ltd

+1.64 (+0.48%)

 USD31.54B N/A N/A
GMAB Genmab A/S

+0.11 (+0.24%)

 USD29.62B 33.28 3.77
SGEN Seagen Inc

+5.02 (+3.17%)

 USD28.78B 49.36 38.34
RPRX Royalty Pharma plc

-0.94 (-2.49%)

 USD22.88B 31.06 13.91
ALNY Alnylam Pharmaceuticals, Inc

+4.63 (+2.59%)

 USD21.02B N/A N/A

ETFs Containing CERS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.55% 55% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.55% 55% F 24% F
Trailing 12 Months  
Capital Gain -14.97% 49% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.97% 49% F 17% F
Trailing 5 Years  
Capital Gain -15.21% 49% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.21% 49% F 21% F
Average Annual (5 Year Horizon)  
Capital Gain 24.66% 58% F 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.66% 58% F 71% C-
Risk Return Profile  
Volatility (Standard Deviation) 65.84% 47% F 27% F
Risk Adjusted Return 37.46% 63% D 55% F
Market Capitalization 0.88B 71% C- 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 9.31 18% F 16% F
Price / Cash Flow Ratio -21.55 79% C+ 80% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -59.35% 48% F 26% F
Return on Invested Capital -46.27% 51% F 17% F
Return on Assets -16.95% 69% D+ 21% F
Debt to Equity Ratio 38.14% 30% F 46% F
Technical Ratios  
Short Ratio 7.35 23% F 13% F
Short Percent 8.47% 37% F 24% F
Beta 1.25 56% F 43% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.